The Fibro-Targets (Targeting cardiac fibrosis for heart failure treatment) project is a multi-disciplinary program involving 11 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure.
Heart failure is a serious disease since it is often irreversible. It is estimated that more than 6.5 million people suffer from heart failure in Europe. It is the leading cause of hospitalization for patients over the age of 65. The incidence is increasing at an alarming rate because of an aging population and the burden of cardiovascular risk factors (diabetes, obesity and high blood pressure). Early interventions targeting key mechanisms, including myocardial interstitial fibrosis, could slow down progression to heart failure.
Fibro-targets ambition to identify biomarkers to predict, monitor and describe the response to myocardial interstitial fibrosis treatments in order to help resolve one of the 21st century’s major health problems that affects elderly people in particular.